ID: ALA3403995

Max Phase: Preclinical

Molecular Formula: C28H39N3O6

Molecular Weight: 513.64

Molecule Type: Small molecule

Representations

Canonical SMILES:  COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OC(=O)NCc2ccccc2)C(C)C)ccc1OC

Standard InChI:  InChI=1S/C28H39N3O6/c1-20(2)31(27(32)22-11-12-24(35-4)25(15-22)36-14-8-13-34-3)19-23-17-29-18-26(23)37-28(33)30-16-21-9-6-5-7-10-21/h5-7,9-12,15,20,23,26,29H,8,13-14,16-19H2,1-4H3,(H,30,33)/t23-,26+/m0/s1

Standard InChI Key:  WGHJKYWWSVIRLL-JYFHCDHNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 513.64

Molecular Weight (Monoisotopic): 513.2839

AlogP: 3.48

#Rotatable Bonds: 13

Polar Surface Area: 98.36

Molecular Species: BASE

HBA: 7

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 9.96

CX LogP: 2.69

CX LogD: 0.20

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.40

Np Likeness Score: -0.70

References

1. Sellner H, Cottens S, Cumin F, Ehrhardt C, Kosaka T, Lorthiois E, Ostermann N, Webb RL, Rigel DF, Wagner T, Maibaum J..  (2015)  trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.,  25  (8): [PMID:25754490] [10.1016/j.bmcl.2015.02.040]

2. Sellner H, Cottens S, Cumin F, Ehrhardt C, Kosaka T, Lorthiois E, Ostermann N, Webb RL, Rigel DF, Wagner T, Maibaum J..  (2015)  trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.,  25  (8): [PMID:25754490] [10.1016/j.bmcl.2015.02.040]

Source

Source(1):

• Scientific Literature